# US 2013/0158502 A1 · Method of inhibiting angiogenesis or invasion or formation of metastases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158502 A1
- Document ID: US20130158502A1
- Status: Published application
- Kind: A1
- Application number: 13/477,181
- Filed: 2012-05-22
- Published: 2013-06-20
- Earliest claimed: 2001-07-26
- Assignees: Inserm
- Inventors: Veronique Trochon; He Lu; Claudine Soria
- Web page: https://patentgrep.com/patent/US20130158502A1

## CPC

- A61N 1/306: {Arrangements where at least part of the apparatus is introduced into the body}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 27/00: Drugs for disorders of the senses
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C12N 9/6489: {Metalloendopeptidases (3.4.24)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating a mammal with a tumor by decreasing intratumoral vessels associated with tumor or inhibiting formation of new intratumoral vessels includes injecting tumor with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by application of electric pulses to site of injection in tumor or injecting muscle of mammal with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by applying electric pulses to site of injection in muscle of mammal, whereby expression of SEQ ID NO: 2 decreases intratumoral vessels associated with tumor, or formation of new intratumoral vessels therein.

## Claims

### Claim 1

A method of treating a mammal with a tumor by decreasing intratumoral vessels associated with the tumor or inhibiting formation of new intratumoral vessels comprising:
a) injecting the tumor with a therapeutically effective amount of an expression plasmid comprising a polynucleotide coding for a therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked to a promoter or an expression control sequence, followed by application of electric pulses to a site of the injection in the tumor; or
b) injecting a muscle of the mammal with a therapeutically effective amount of an expression plasmid comprising a polynucleotide coding for a therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein the polynucleotide sequence is operably linked to a promoter or an expression control sequence, followed by applying electric pulses to a site of the injection in the muscle of the mammal,
whereby expression of SEQ ID NO: 2 decreases intratumoral vessels associated with the tumor, or formation of new intratumoral vessels therein.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said polynucleotide sequence consists of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said expression plasmid coding for the therapeutic peptide consisting of SEQ ID NO: 2 is administered by injection in said muscle of the mammal with a tumor followed by application of electric pulses to the site of injection in said muscle of the mammal with a tumor.

### Claim 4

A method of treating a mammal with metastases by decreasing intratumoral vessels associated with the metastases or inhibiting formation of new intratumoral vessels comprising:
a) injecting a muscle of the mammal with a therapeutically effective amount of an expression plasmid comprising a polynucleotide coding for a therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein the polynucleotide sequence is operably linked to a promoter or an expression control sequence;
b) followed by applying electric pulses to a site of the injection in the muscle,
whereby expression of SEQ ID NO: 2 decreases intratumoral vessels associated with the metastases or formation of new intratumoral vessels.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said polynucleotide sequence consists of SEQ ID NO: 1.

### Claim 6 (depends on 4)

The method according to claim 4, wherein said expression plasmid coding for the therapeutic peptide consisting of SEQ ID NO: 2 is administered by injection in said muscle of the mammal with metastases followed by application of electric pulses to the site of injection in said muscle of the mammal with metastases.